News | April 05, 2021
Piramal Enterprises forays into peptide with Hemmo Pharma : ICICI Securities
ICICI Securities expects Hemmo to grow its revenue at a CAGR of 30.0% over FY21E-FY23E
ICICI Securities expects Hemmo to grow its revenue at a CAGR of 30.0% over FY21E-FY23E
GSKP announced sale of its newly constructed manufacturing plant at Vemgal, Karnataka to Hetero Labs for a cash consideration of Rs1.8bn
India produces 60% of the world’s vaccine
The vaccine was 85 percent effective in preventing severe disease across all regions.
Besides powering the drug discovery efforts, phytopharmaceuticals have a huge potential to create a niche market for itself, thereby helping to expand the bio-economy.
The company received approval for 2-Methyl-5Nitro-Imidazole (2-MNI) with a committed production capacity of 4,000 MT per annum.
Pharma industry is ready to embrace technology platforms with a keen focus on automation in manufacturing and digital health investment.
Bharat Biotech expects to share further details of the trial results as additional data become available.
Merck forecasts organic growth of EBITDA pre in a high single-digit to low teens percentage range in 2021.
A mix of favorable government policies and a positive environment will create a win-win situation for all stakeholders
Subscribe To Our Newsletter & Stay Updated
